Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Did you all see this :
TOKYO, Oct 19 (Reuters) - Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm depending on the success of the cell-targeting therapies.
French pre-clinical biotech Mablink Biosciences has confirmed earlier rumors that it has agreed to a takeover bid from acquisition-hungry US pharma major Eli Lilly .
This is the 6th deal by Lilly this year.
They are presenting at ESMO
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
The majors are all presenting and they all want to talk to Avacta, who is not presenting, but no doubt attending by request.
Get on board AM.
Mega size buyers joining us early from NY, this time they will not hide, Convert. Shares already pre sold.
+
ESMO conference with several mayors incl Bayer, Lilly all over precision Oncology just like Novartis( point Biopharma)day long presentation.
Guess what, Avacta attending
Thermo Fisher Scientific doing another transaction.
:We are excited to announce that we have entered into an agreement to acquire
@OlinkProteomics
, a leading provider of next generation proteomics solutions. We look forward to welcoming their team to Thermo Fisher. Learn more in our Press Release: https://bit.ly/3s3Owm2
This deal with $50 mill upfront and potential milestone payments up to $2bill shows the appetite for deals among the majors, just days after AACR.
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases | Monte Rosa Therapeutics
And much more to come next week, post Saturday’s poster presentation.
Novartis attending presentation.
The company have said recently Precision Oncology is where they want to be.
Novartis, Lilly and Roche and Takeda big fans of Fiona.
More to come!
Monday opening price, comfortably in the sixties.
With P1b no longer required and when the 2 weekly study shows the expected result, one would expect Dr. Tap and Avacta using the 2 weekly study for P2.
Useful to have est. cost savings which should be significant.
The Poster presentation Saturday should attract an awful lot of interest , with of course Novartis attending.
Watch the size buyers this afternoon writing tickets and pushing the price easily back above 160!
Yes that is how these conferences works, it does put someone like Fiona on the spot for Q&A with Audience.
An RNS in the morning U.K. time, would certainly lift the profile of the company even faster.
Hopefully you all took advantage of the share price two weeks ago.
One could off course also argue, that we have a stock moving higher supported by above average volume and market anticipating the upcoming presentation at AACR conference highlighting AVA3996, AVA6000 and indeed the entire AVA Platform and it‘s potential value going forward.When asked before, industry observers have suggested one applies a 1 billion dollars to each AVA as an average.
The market is growing at pace and we have barely begun.
Good luck to everybody who have taken profit, just don’t forget to jump back on again, we are leaving very soon!